H. Dai

The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency.

R. Boyd, T. Marbury, S. Terra, 2011, British journal of clinical pharmacology.

A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.

S. Schwartz, J. Teeter, S. Terra, 2011, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance

P Chan, M. Tortorici, W. Byon, 2013, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of a Novel Sorbitol Dehydrogenase Inhibitor in Healthy Participants

Z. Landau, P. Oates, G. Preston, 2010, Journal of clinical pharmacology.

Metabolism, Excretion, and Pharmacokinetics of ((3,3-Difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a Dipeptidyl Peptidase Inhibitor, in Rat, Dog and Human

C. Prakash, Hao Sun, Tim F. Ryder, 2012, Drug Metabolism and Disposition.

The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency.

R. Boyd, T. Marbury, S. Terra, 2011, British journal of clinical pharmacology.

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor PF‐734200 added to metformin in Type 2 diabetes

J. Rosenstock, J. Teeter, P. Norwood, 2011, Diabetic medicine : a journal of the British Diabetic Association.

Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.

B. Hirshberg, G. Preston, S. Gustavson, 2011, Diabetes research and clinical practice.